Sorrento Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative therapies for cancer, autoimmune diseases, inflammatory conditions, and neurodegenerative disorders. The company leverages its proprietary G-MAB antibody library to create a diverse range of treatments, including chimeric antigen receptor T-cell therapies, bispecific antibodies, and antibody-drug conjugates. Key products in development include anti-CD38 CAR-T therapy for multiple myeloma and a non-opioid neurotoxin, resiniferatoxin, aimed at treating severe pain in late-stage cancer and osteoarthritis. Sorrento also explores drug delivery technologies such as Sofusa, which targets the lymphatic system, and ZTlido, a lidocaine delivery system for postherpetic neuralgia. Additionally, the company is involved in various collaborations to enhance its research and development efforts, including projects focused on COVID-19 therapeutics. With a commitment to addressing significant unmet medical needs, Sorrento Therapeutics aims to advance its diverse pipeline through both innovative drug development and strategic partnerships.
Ancora Medical is a privately held medical technology company focused on developing innovative catheter technology aimed at improving surgical pain management. The company's anchoring catheter and needle combination is designed to administer long-lasting anesthesia during the preoperative, perioperative, and postoperative phases of general and orthopedic surgery. Ancora's technology enhances the precision of nerve localization by utilizing electrical impulses from a nerve stimulator in conjunction with ultrasound visualization. This approach aims to provide healthcare professionals with an effective and affordable solution for managing surgical pain, ultimately improving patient outcomes.
Virex Health
Acquisition in 2022
Virex Health is a biotechnology company focused on enhancing public health through innovative diagnostic solutions. It manufactures rapid point-of-care testing kits that utilize a glucometer and a specialized test strip, which allow for affordable and scalable diagnostic services. These kits are designed for a variety of applications, including COVID-19 testing and early cancer detection. By enabling widespread testing in diverse environments such as homes, workplaces, schools, and public spaces, Virex Health aims to improve accessibility to advanced diagnostics and contribute to better health outcomes globally.
Aardvark Therapeutics
Series B in 2021
Aardvark Therapeutics, Inc. is a biopharmaceutical company based in San Diego, California, focused on developing and commercializing small molecule therapeutics for obesity and rare genetic metabolic disorders. Founded in 2017 by Tien Lee, the company has introduced Bittera, a first-in-class oral composition designed to selectively disrupt hunger signaling and regulate energy homeostasis. This innovative therapeutic approach provides clinicians with an effective and safe treatment option for obesity-related diseases, without interfering with nutrient absorption. Aardvark Therapeutics aims to address significant health challenges associated with obesity and metabolic conditions through its specialized drug development efforts.
Celularity
Post in 2021
Celularity is a clinical-stage biotechnology company focused on advancing cellular medicine through the development of off-the-shelf placental-derived allogeneic cell therapies. Its product pipeline includes unmodified and genetically modified natural killer (NK) cells, CAR-engineered T cells, and mesenchymal-like adherent stromal cells. The company targets various health conditions, including cancer, immunologic disorders, infectious diseases, and degenerative illnesses. Celularity leverages the unique biology of the placenta, aiming to create effective and accessible therapies to address significant unmet medical needs. In addition to its cell therapy initiatives, Celularity operates a bio-banking segment, which contributes substantially to its revenue.
ACEA Therapeutics
Acquisition in 2021
ACEA Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative treatments for lung cancer, lymphoma, and systemic lupus erythematosus. Founded in 2017 and based in San Diego, California, with additional operations in China, ACEA Therapeutics is engaged in drug discovery and development, including targeted therapies and immunotherapies. Its product pipeline features several candidates, including Abivertinib, AC0058, AC0002, and AC0078, aimed at addressing cancer and autoimmune disorders. The company has established drug manufacturing and commercial capabilities in China, which enhances its control over the supply chain and ensures timely delivery of high-quality products to patients. Through its research and development efforts, ACEA Therapeutics seeks to improve the lives of patients facing life-threatening diseases.
SmartPharm Therapeutics
Acquisition in 2020
SmartPharm Therapeutics is a development-stage biopharmaceutical company focused on creating non-viral gene therapies for serious and rare diseases. Founded in 2017 and based in Cambridge, Massachusetts, SmartPharm aims to develop a pipeline of gene-encoded therapeutics that allow patients' bodies to produce essential biologics for conditions requiring such treatments, including enzyme replacement and tissue restoration. The company's innovative platform emphasizes minimal immunogenicity, re-dosability for patients, and scalable manufacturing, while also seeking to simplify regulatory processes. By leveraging insights gained from previous gene therapy developments, SmartPharm integrates advanced technologies to produce optimal gene-encoded therapies, thereby enhancing the therapeutic benefits for patients without the complications associated with viral vectors.
Celularity
Venture Round in 2018
Celularity is a clinical-stage biotechnology company focused on advancing cellular medicine through the development of off-the-shelf placental-derived allogeneic cell therapies. Its product pipeline includes unmodified and genetically modified natural killer (NK) cells, CAR-engineered T cells, and mesenchymal-like adherent stromal cells. The company targets various health conditions, including cancer, immunologic disorders, infectious diseases, and degenerative illnesses. Celularity leverages the unique biology of the placenta, aiming to create effective and accessible therapies to address significant unmet medical needs. In addition to its cell therapy initiatives, Celularity operates a bio-banking segment, which contributes substantially to its revenue.
Semnur Pharmaceuticals
Acquisition in 2016
Semnur Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the development of innovative non-opioid medications aimed at treating lumbar radicular pain. The company focuses on creating products that address the needs of pain management practitioners and their patients, particularly those suffering from back pain. By prioritizing clinical and commercial development, Semnur aims to enhance the efficacy and safety of pain management therapies, ultimately improving treatment outcomes for underserved patient populations.
SCILEX Holding
Acquisition in 2016
Scilex Holding Co is a pharmaceutical company specializing in acquiring and commercializing late-stage prescription products focused on non-opioid pain management. Its primary product, ZTlido, is a topical lidocaine system used to relieve nerve pain associated with postherpetic neuralgia. Additionally, Scilex is developing Gloperba, an oral colchicine solution for preventing painful gout flares in adults. The company's pipeline includes SP-102, a viscous gel formulation of a corticosteroid for epidural injections, and SP-103, a Phase 2 triple-strength capsaicin cream for neuropathic pain.
Globavir Biosciences
Venture Round in 2015
Globavir, founded in 2011 by Dr. Shalabh Gupta, focuses on developing therapeutics and diagnostics for infectious diseases. The company leverages multiple licenses from Stanford University to advance its research and product development. Globavir acquired BioCycive in 2014, integrating it as a wholly owned subsidiary. This acquisition allowed Globavir to expand its capabilities, leading to a partnership in 2015 with Sorrento Therapeutics to advance BioCycive's lead program. Additionally, in 2016, Globavir collaborated with Bio-Rad to enhance its diagnostic test offerings. The company addresses a range of infectious diseases, including dengue, West Nile, chikungunya, and Ebola, while also extending its research efforts into cancer treatment.
NantiBodyFc
Private Equity Round in 2015
NantiBodyFc operates in the healthcare industry. Founded in 2015, the company is headquartered in Cumming, Georgia, United States.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.